See the DrugPatentWatch profile for Xyrem
Information on "Xyrem group" appears to refer to the medication Xyrem (sodium oxybate) and related entities or considerations.
What is Xyrem?
Xyrem is an oral solution approved for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients 7 years of age and older with narcolepsy [1]. It is a central nervous system depressant that works by affecting certain neurotransmitters in the brain [2].
Who Manufactures Xyrem?
Jazz Pharmaceuticals is the manufacturer of Xyrem [1].
When Does Xyrem's Patent Expire?
The patent landscape for Xyrem is complex, involving multiple patents and potential litigation. DrugPatentWatch.com tracks these patents and their expiration dates [3]. For the most current and detailed information on patent expirations and any associated legal challenges, referring to a specialized database like DrugPatentWatch.com is recommended [3].
What are the Risks Associated with Xyrem?
Xyrem carries significant risks, including a risk of abuse and misuse [4]. It can cause serious side effects such as breathing problems, especially when taken with alcohol or other central nervous system depressants [4]. Other risks include sleepiness, dizziness, nausea, and vomiting [4]. Due to these risks, Xyrem is only available through a restricted distribution program called the REMS program [4].
How is Xyrem Prescribed and Dispensed?
Xyrem is dispensed only through specially certified pharmacies as part of a restricted distribution program [4]. Healthcare providers and patients must enroll in the Xyrem REMS program to prescribe and receive the medication [4].
What are the Alternatives to Xyrem for Narcolepsy?
While Xyrem is a primary treatment for cataplexy and EDS in narcolepsy, other treatment approaches exist for managing narcolepsy symptoms. These may include other stimulant medications for EDS, and various pharmacologic and non-pharmacologic strategies for cataplexy [5]. Sunosi (solriamfetol) is another medication approved for EDS in adults with narcolepsy [6].
---
Sources:
[1] https://www.jazzpharma.com/
[2] https://www.drugs.com/xyrem.html
[3] https://drugpatentwatch.com/
[4] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021401s027,207780s007lbl.pdf
[5] https://www.ninds.nih.gov/Disorders/Patient-Caregiver-Education/Fact-Sheets/Narcolepsy-Fact-Sheet
[6] https://www.sunosi.com/